1 Amyloid Research and Treatment Center Fondazione IRCCS Policlinico San Matteo University of Pavia, Italy
2 University Hospital Fondazione IRCCS Policlinico San Matteo Amyloidosis Research and Treatment Center Established in 1986 Clinical integrated center Center Carlo Bernasconi Research center Biotechnology Research Lb Labs Italian Amyloidosis Study Group 68 centers Research collaborations International
3 University Hospital Fondazione IRCCS Policlinico San Matteo Amyloidosis Research and Treatment Center Increase of patients evaluated each year at the Amyloidosis Research and Treatment Center
4 Distribution of 1689 patients with systemic amyloidosis referred to the Pavia Amyloidosis Research and Treatment Center Reactive (AA) 8% Familial 20% Primary (AL) 72%
5 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center More than 200 new patients with systemic amyloidosis are evaluated each year. And additional > 3,000 follow-up evaluations are performed every year. The outpatient facility (2,150 square feet) allows for an extensive evaluation of patients within the Center.
6 Fondazione IRCCS Policlinico San Matteo - Univ. di Pavia Amyloid Research and Treatment Center Italian Amyloidosis Study Group 68 medical centers participate in the network Web site: A common diagnostic and therapeutic protocol is periodically discussed and updated: last update in Rome May next update in Turin May
7 Typing of amyloid deposits Ultrastructural (EM) immunohistochemistry with gold-labelled Ab sensitivity 93%, specificity 99% based on 598 tests performed on abdominal fat aspirates anti- antibody anti- antibody anti-ttr antibody anti-apolipoprotein A-I antibody
8 TYPING AMYLOIDOSIS: PROTEOMICS ON ABDOMINAL FAT ASPIRATE 250 pi 3 10 Patient Lavatelli et al, Mol Cell Proteomics. 2008;7: pi 3 10 Control MW (kda a) MW (kda a) LC sequence (from bone marrow) and coverage (underlined) DFMLIQPHSV SESPGKTVTI SCTRSSGNIA SNYVQWYQQR PGSSPTTVIY EDNQRPSGVP DRFSGSIDSS SNSASLTISG LKTEDEADYY CQSDESSVHW VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS Intensity T T (Ox) m/z 3000 Lambda 6 light chain
9 CARDIAC AMYLOID IMAGING ACCURACY OF 99mTc-APROTININ SCINTIGRAPHY FOR THE DETECTION OF MYOCARDIAL AMYLOIDOSIS: LONG-TERM FOLLOW-UP OF 108 PATIENTS SENSITIVITY 0.95 SPECIFICITY 0.97 ACCURACY 0.96 Aprile et al, Eur J Nucl Med. 1995;22:
10 AMYLOID IMAGING 99m Tc-Aprotinin Scintigraphy in Amyloidosis Schaadt et al, J Nucl Med. 2003;44: Focal accumulations of 99m Tc aprotinin were seen in different organs of 22 patients with a total of 90 lesions, of which 20 were confirmed by biopsy or autopsy. Scintigraphy revealed silent amyloid deposits in at least 5 patients who later developed clinical symptoms. A 64-y-old man (patient 5) with renal AL amyloidosis. i Whole-body scintigram shows pathologic uptake in heart,liver, and right lung or pleura (anterior view). Patient had no symptoms from heart at time of scintigraphy but died of heart failure 8 mo later.
11 The iodinated anthracycline 4 -iodo-4 -deoxydoxorubicin binds specifically and with very high affinity to amyloid fibrils PNAS 1995;92:2959 Am J Pathol 2000;156:1919 Promotes fibril disaggregation in vitro Am J Pathol 2000;156:1919 Biochem J 2000;351:273 FASEB J 2003;17:803 Induces 15% (15 mg/m 2 )-40% (80-30 mg/m 2 ) of responses in AL patients Blood 1995;86:855 Blood 1999;93:1112 Amyloid 2002;9:24 best use in conjunction with chemotherapy
12 4 -iodo-4 -Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters Cardoso I, Merlini G, Saraiva M, FASEB J. 2003; 17: Control I 4 -iodo-4 -deoxydoxorubicin Doxycycline I-Dox 100 M 360 M
13 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center Clinical research new diagnostic approaches (proteomics) new imaging techniques development of novel drugs (phase I-II II and III trials) Phase I-II: bortezomib in AL amyloidosis Fx-1006 in ATTR amyloidosis Phase II: Phase III: CLD in AL amyloidosis Diflunisal in ATTR amyloidosis Doxycyclin in ATTR amyloidosis MDex vs BMDex
14 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center The Amyloid Center and the Biotechnology Research Laboratories (BRL) are a single unit within the University Hospital, combining clinical and basic research. The BRL laboratory space is approximately 4,300 square feet. The BRL comprises a serum/tissue bank of more than 1000 amyloid patients. The BRL instruments allow all the proteomic and genetic studies that are part of the project. The BRL facilities include state-of-the-art equipment, for protein purification and analysis and for proteomics studies including mass spectrometers (MALDI-TOF, Q-TOF) operated by expert personnel of the BRL.
15 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center
16 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center Basic research Mechanism of amyloid formation in 2m and apoai amyloidosis Amyloid tissue targeting g JBC 2006;281:
17 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center Basic research Amyloid tissue damage: investigating amyloid cardiotoxicity production of recombinant complete light chains testing the toxicity on cardiomyocytes y Systolic Shorthening ( m/sec) Diastolic Lengthening ( m/sec) * * -120 Control Cardiac AL Non Cardiac AL 0 Control Cardiac AL Non Cardiac AL
18 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center Collaborations EURAMY Group (Uppsala, Umea, Groningen, Berlin, Limoges, Porto) National Amyloid Centre, London (Prof. M. Pepys, Prof. P. Hawkins) biomarkers new drugs Instituto de Biologia Molecular e Celular, Porto, Portugal (Prof. Maria J. Saraiva) new drugs Institute t of Neuropathology, University it Hospital of Zürich (Prof. A. Aguzzi) animal models Boston University Amyloid Program (Dr. D. Seldin, Dr. C. Costello) proteomics, clinical trials Mayo Clinic Monoclonal Gammopathy Centre (Dr M Gertz Dr Dispenzieri) Mayo Clinic, Monoclonal Gammopathy Centre (Dr. M. Gertz, Dr. Dispenzieri) clinical trials
19 University of Pavia and University Hospital San Matteo Amyloid Research and Treatment Center Vittorio Bellotti Vittorio Perfetti Laura Obici i Giovanni Palladini Francesca Lavatelli Paola Russo Mario Nuvolone Laura Verga Monica Stoppini Irene Zorzoli Palma Mangione Sofia Giorgetti Simona Casarini Simona Donadei Valentina Navazza Silvia Gabba Sara Marini i Alberto Bovera Chiara Crosignani Fondazione IRCCS Policlinico San Matteo Pavia
Evidence Report/Technology Assessment Number 160 Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
HEALTH FOR ALL FACULTY OF HEALTH SCIENCES UNIVERSITY OF SOUTHERN DENMARK The Faculty of Health Sciences consists of eight departments: DEPARTMENT OF CLINICAL RESEARCH DEPARTMENT OF MOLECULAR MEDICINE DEPARTMENT
Today, the Università degli Studi di Perugia is a modern, multi-campus educational institution whose primary aim is to provide the highest quality degree programmes and advanced scientific research and
Special Section: Cancer in Children & Adolescents Overview The news of a cancer diagnosis is never welcome, but may be even more unexpected and difficult when the disease is diagnosed in a child or adolescent.
Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Needfor Life Threatening or Irreversibly Debilitating Diseases or Conditions Guidance for Industry and Food
Evaluation of Sex-Specific Data in Medical Device Clinical Studies Guidance for Industry and Food and Drug Administration Staff Document issued on August 22, 2014. The draft of this document was issued
Unclassified ENV/JM/MONO(2000)7 ENV/JM/MONO(2000)7 Or. Eng. Unclassified Organisation de Coopération et de Développement Economiques OLIS : 20-Dec-2000 Organisation for Economic Co-operation and Development
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
Guidance for Industry and Review Staff Product Profile A Strategic Development Process Tool DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Guidance for Industry Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
WHO/NMH/MNC/03.1 Original: English Screening for Type 2 Diabetes Report of a World Health Organization and International Diabetes Federation meeting World Health Organization Department of Noncommunicable
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
Farchi et al. BMC Pediatrics 2014, 14:36 STUDY PROTOCOL Piccolipiù, a multicenter birth cohort in Italy: protocol of the study Open Access Sara Farchi 1, Francesco Forastiere 2, Liza Vecchi Brumatti 3,
Down Syndrome Directions The National Institutes of Health Research Plan on Down Syndrome Down Syndrome Directions National Institutes of Health Research Plan on Down Syndrome U.S. Department of Health
Should I Enter a Clinical Trial? A Patient Reference Guide for Adults with a Serious or Life-Threatening Illness A Report by ECRI Commissioned by AAHP ECRI February 2002 Should I Enter a Clinical Trial?
Chapter 8. Selection of Data Sources Cynthia Kornegay, Ph.D.* U.S. Food and Drug Administration, Silver Spring, MD Jodi B. Segal, M.D., MPH Johns Hopkins University, Baltimore, MD Abstract The research
Infectious Disorders - Drug Targets 2007, 7, 105-119 105 Challenges Associated with Current and Future TB Treatment M. Laurenzi*, A. Ginsberg and M. Spigelman The Global Alliance for TB Drug Development,
Genetic Testing for Cancer: What You Need to Know Here is some basic information about genetic testing and how it s used to learn about inherited cancer risk. It will help you understand what genetic testing
Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take?* Pharma 2020: Virtual R&D 1 Table of contents Innovation essentials 1 Getting to know ourselves 4 Making research more
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
European Heart Journal (2006) 27, 1341 1381 doi:10.1093/eurheartj/ehl001 ESC guidelines y Guidelines on the management of stable angina pectoris: executive summary The Task Force on the Management of Stable
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
Drug Discovery and Development UNDERSTANDING THE R&D PROCESS This is a fantastic time to be doing drug discovery. We have an incredible wealth of knowledge that has been generated over the past few years.
Good Practice Guidelines in the process of Organ Donation Good Practice Guidelines in the process of Organ Donation National Transplant Organization, 2011 That Spain is the leader in organ donations has
A Review of the Definition for Multiple Primary Cancers in the United States Workshop Proceedings From December 4-6, 2002, in Princeton, New Jersey Editor: Holly L. Howe, Ph.D. Executive Director NAACCR
CONCISE REVIEW FOR CLINICIANS PROLONGED PT AND APTT How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults ARIF H. KAMAL, MD; AYALEW